Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,095 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bladder Cancer Clear all
Completed Phase 2 Interventional

Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer

NCT00028860
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
filgrastim, carboplatin, gemcitabine hydrochloride, ifosfamide, paclitaxel, adjuvant therapy
Biological · Drug · Procedure
Lead sponsor
Tulane University Health Sciences Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 23, 2026, 2:45 AM EDT
Withdrawn Phase 2 Interventional

Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer

NCT02718742
View directory record Official record
Conditions
Recurrent Bladder Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma
Interventions
Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Quality-of-Life Assessment
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 23, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract

NCT03159143
View directory record Official record
Conditions
Metastatic Transitional Cell Cancer of the Urothelial Tract
Interventions
Docetaxel, Oxaliplatin
Drug
Lead sponsor
Leonard Appleman
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 23, 2026, 2:45 AM EDT
Completed Phase 1 Interventional

A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

NCT04440943
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, MSI-H Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Other Solid Tumors
Interventions
CDX-527
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 23, 2026, 2:45 AM EDT
Terminated Phase 2 Interventional Results available

Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery

NCT00268450
View directory record Official record
Conditions
Bladder Cancer
Interventions
bevacizumab, cisplatin, gemcitabine hydrochloride, paclitaxel, cysectomy
Biological · Drug · Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
4
States / cities
Charleston, South Carolina • Florence, South Carolina • Mt. Pleasant, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 23, 2026, 2:45 AM EDT
Recruiting Not applicable Interventional

Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

NCT06101277
View directory record Official record
Conditions
Small Bowel Cancer, Colorectal Cancer, Appendiceal Cancer, Biliary Cancer, Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Oligoprogressive
Interventions
Ablative local therapy
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2039
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 23, 2026, 2:45 AM EDT
Completed Phase 2 Interventional

Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium

NCT00310011
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
cisplatin, gemcitabine hydrochloride, paclitaxel, conventional surgery
Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
3
States / cities
Charlotte, North Carolina • Greensboro, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 23, 2026, 2:45 AM EDT
Completed Phase 2 Interventional

Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium

NCT00080795
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
filgrastim, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, ifosfamide, conventional surgery, neoadjuvant therapy
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced Oct 23, 2026, 2:45 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors

NCT01517464
View directory record Official record
Conditions
Neoplasm
Interventions
SGT-94
Genetic
Lead sponsor
SynerGene Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 23, 2026, 2:45 AM EDT
Recruiting Not applicable Interventional

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

NCT06394869
View directory record Official record
Conditions
Hematuria - Cause Not Known
Interventions
Cxbladder Triage Plus
Diagnostic Test
Lead sponsor
Pacific Edge Limited
Industry
Eligibility
18 Years to 88 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
20
States / cities
Homewood, Alabama • Mobile, Alabama • Fresno, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 23, 2026, 2:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

NCT02001623
View directory record Official record
Conditions
Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer (CRPC), Esophagus Cancer, Lung Cancer(NSCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
Tisotumab Vedotin (HuMax-TF-ADC)
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
Orange, California • New Haven, Connecticut • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 23, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer

NCT02281383
View directory record Official record
Conditions
Bladder Cancer, High Risk Superficial
Interventions
Bacillus Calmette-Guérin (BCG)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 23, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

NCT04919512
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
TAR-200, Cetrelimab
Drug · Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 23, 2026, 2:45 AM EDT
Withdrawn Phase 3 Interventional

Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer

NCT03298958
View directory record Official record
Conditions
Bladder Cancer
Interventions
Rapamycin, Placebo Oral Tablet
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 23, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy

NCT00919061
View directory record Official record
Conditions
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Interventions
Gemcitabine, Cisplatin, Sorafenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 23, 2026, 2:45 AM EDT
Completed No phase listed Observational

Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)

NCT06126796
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
CxBladder Monitor, Cystoscopy
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 23, 2026, 2:45 AM EDT
Recruiting No phase listed Observational

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

NCT06349642
View directory record Official record
Conditions
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Liver Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Skin Neoplasm, Metastatic Malignant Solid Neoplasm, Resectable Lung Non-Small Cell Carcinoma, Early Stage Lung Non-Small Cell Carcinoma, Resectable Malignant Solid Neoplasm, Resectable Triple-Negative Breast Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Recurrent Cervical Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Malignant Skin Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Tissue Collection
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 23, 2026, 2:45 AM EDT
Completed Phase 1 Interventional

Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer

NCT03359239
View directory record Official record
Conditions
Urothelial/Bladder Cancer, Nos
Interventions
Atezolizumab, PGV001, Poly ICLC, Normal saline
Drug · Biological
Lead sponsor
Matthew Galsky
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 23, 2026, 2:45 AM EDT
Not yet recruiting Phase 3 Interventional

Effectiveness of Medical and Environmental Interventions to Reduce Cystoscopy Discomfort (CystoDiscomfort)

NCT07795255
View directory record Official record
Conditions
Bladder (Urothelial, Transitional Cell) Cancer, Hematuria
Interventions
Headphones, Dwell time 5-10 minutes, Dwell Time more than 10 minutes
Device · Drug
Lead sponsor
Florian Schroeck
Federal
Eligibility
18 Years and older
Enrollment
1,740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina • Wilmington, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 23, 2026, 2:45 AM EDT
Completed No phase listed Observational Results available

Perioperative Hypogonadism in Men Undergoing Radical Cystoprostatectomy for Bladder Cancer

NCT03063125
View directory record Official record
Conditions
Bladder Cancer, Low Testosterone Levels
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 23, 2026, 2:45 AM EDT
Completed No phase listed Observational

A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer

NCT07386847
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma, Urothelial Cancer, Urothelial Carcinoma, Locally Advanced or Metastatic Urothelial Carcinoma
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 23, 2026, 2:45 AM EDT
Completed Not applicable Interventional

The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma

NCT02700464
View directory record Official record
Conditions
Bladder Cancer
Interventions
Bladder EpiCheck Urine Test, Cystoscopy and pathology
Device · Procedure
Lead sponsor
Nucleix Ltd.
Industry
Eligibility
22 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
10
States / cities
Denver, Colorado • Baltimore, Maryland • Troy, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 23, 2026, 2:45 AM EDT
Withdrawn Not applicable Interventional

Intervention Protocol for Automated Point-of-Care Surveillance of Outpatient Delays in Cancer Diagnosis

NCT01710293
View directory record Official record
Conditions
Lung Cancer, Bladder Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Breast Cancer
Interventions
Communication of Patients Lost to Follow-up to Providers
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Chicago, Illinois • Hines, Illinois • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 23, 2026, 2:45 AM EDT
Completed Phase 2 Interventional

Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter

NCT00066352
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
bortezomib
Drug
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
11
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Oct 23, 2026, 2:45 AM EDT